The following year, Andrew Dhawan and colleagues characterized collateral sensitivities to several tyrosine kinase inhibitors (TKIs) in ALK-positive non-small cell lung cancer (NSCLC). The gene discussed is ALK; the disease is non-small cell lung carcinoma.